Can an inhaled powder calm the painful Cold-Finger attacks of scleroderma?
NCT ID NCT07748000
First seen Aug 05, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tests an inhaled powder called LIQ861 (treprostinil) in adults with scleroderma who have frequent, painful Raynaud's attacks—episodes where fingers or toes turn color and become numb or tingly. About 75 participants will be randomly assigned to receive either a dose that gradually increases or a fixed low dose, to see which doses are safe and comfortable. The study also looks at whether the treatment reduces the number, severity, and impact of these attacks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LIQ861 (treprostinil) inhalation powder
- What this could lead to
- If it works, this could offer a new way to reduce the frequency and severity of painful Raynaud's attacks in people with scleroderma, improving daily comfort and quality of life.
- What could go wrong
- This is an early (phase 2) study with a small number of participants, so results may not apply broadly. The treatment may cause side effects or may not effectively reduce attacks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.